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Abstract
Background. Hilar cholangiocarcinoma is a rare tumour which is best managed by an aggressive surgical approach. The role of
adjuvant or neoadjuvant radiation therapy, chemotherapy or chemoradiation remains controversial, as no prospective
randomized studies have been performed. Methods. This review summarizes the recent literature regarding the role of
radiation, chemotherapy and chemoradiation in hilar cholangiocarcinoma. The results of a biliary cancer questionnaire
regarding current treatment strategies are also reported. Results. A number of retrospective studies have shown that patients
treated with adjuvant radiation therapy have prolonged survival compared with untreated patients. However, most of these
reports did not control for tumour stage or performance status. A carefully controlled trial from the Johns Hopkins Hospital
did not demonstrate any benefit for adjuvant radiation therapy. A number of phase II trials of chemotherapy have
demonstrated modest response rates (20–40%). The best responses have been reported with 5-fluorouracil (5-FU) in
combination with interferon-alpha or with leucovorin and mitomycin C. Recent non-randomized reports of chemoradiation
with 5-FU with or without gemcitabine as the radiosensitizer suggest, but do not prove, improved survival. Adjuvant
chemoradiation is currently being employed at specialized centres most often in the Americas (71%) and the Asia/Pacific
region (55%) and to a lesser degree in Europe (29%). Discussion. The only chance for long-term survival in patients with hilar
cholangiocarcinoma is complete resection with negative margins. Neither radiation therapy nor chemotherapy alone has been
proven to prolong survival in completely or partially resected patients or in unresected patients. Recent uncontrolled data
suggest that chemoradiation may improve survival in resected and locally unresectable patients. However, prospective,
randomized multicentre trials need to be performed to confirm efficacy.
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Introduction
Cholangiocarcinoma is an uncommon tumour that may
occur anywhere along the intrahepatic or extrahepatic
biliary tree. In the United States approximately
4000–5000 cholangiocarcinomas are diagnosed per year.
The hepatic duct bifurcation is the most frequently
involved site, and approximately 60–80% of cholangio-
carcinomas are found in this perihilar region [1].The role
of radiation therapy, chemotherapy and chemoradiation
as adjuvants to surgical resection inpatientswithperihilar
cholangiocarcinoma remains controversial. Aggressive
surgical resection obtaining a negative microscopic
margin offers the only chance for long-term survival.
Unfortunately, many patients will only be candidates for
palliative bypass or operative or non-operative intubation
aimed to provide biliary drainage and prevent cholangitis
and hepatic failure. Radiation therapy, chemotherapy
and/or chemoradiation also can be used in these patients
with non-resectable disease in an attempt to palliate
symptoms and extend survival.
Five-year survivals as high as 30–40% have been
reported for perihilar cholangiocarcinomas in the
subset of patients that can be resected with negative
microscopic margins [1–3]. Unfortunately, despite
recent advances in radiological imaging and improved
staging of perihilar cholangiocarcinoma, less than half
of the tumours are resectable at the time of exploration.
In patients undergoing potentially curative resection
for hilar cholangiocarcinomas loco-regional recurrence
is found approximately 60% of the time while distant
metastases are seen with or without local recurrence in
almost 40% [4]. Therefore, many authorities recom-
mend the addition of adjuvant chemoradiation for
patients with resected perihilar cholangiocarcinoma.
Radiation therapy
Initially, bile duct tumours were thought to be
radioresistant, but several studies have shown
that radiotherapy can palliate symptoms and may
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contribute to improvement in survival. Ionizing
radiation likely acts by the production of free radicals
that cause damage to DNA resulting in double-
stranded DNA breaks. These DNA lesions are unable
to be repaired or are repaired inadequately in tumour
tissue; and as a result, the malignant cells are unable to
divide. Therapeutic gain is achieved by the difference
in repair capacity and fidelity of repair of DNA lesions
in tumour as opposed to normal tissue. Radiotherapy is
delivered as a fractionated daily dose allowing normal
tissue to repair DNA damage between treatments.
Tumours repair this damage less well. Factors which
limit the usefulness of radiotherapy in bile duct
tumours include the inherent sensitivity of tumours
to radiation, hypoxic radioresistant regions within
tumour, the repopulation of surviving tumour cells,
and the initial number of viable tumour cells in the
resected field.
Radiation therapy has been evaluated in patients
with cholangiocarcinoma using a variety of methods
including external beam radiotherapy, intraoperative
radiotherapy, internal radiotherapy, radioimmuno-
therapy, and charged particle radiation. External beam
radiotherapy has been the most commonly used
modality and is typically administered to a total dose of
45–60 Gy. Internal radiotherapy is normally delivered
through either percutaneous or endoscopically placed
biliary stents using iridium-192 as the radiation source.
Total radiation doses may vary from 20 to 60 Gy
up to 1 cm from the source. Radioimmunotherapy
has also been performed with iodine-131 anti-CEA
(carcinoembryonic antigen).
Multiple retrospective analyses have suggested that
radiation therapy augments survival in patients with
perihilar cholangiocarcinoma. In a recent study from
Japan, Todoroki and colleagues [5] examined 63
patients who underwent resection of a perihilar
cholangiocarcinoma. Twenty-one patients underwent
resection alone and 42 patients received adjuvant
radiation therapy. Intraoperative radiation therapy
(IORT) alone was given to 12 patients (mean dose
21.0+0.6 Gy), 8 patients were treated with post-
operative radiation therapy (PORT) (mean dose
43.6+1.4 Gy) and 22 patients received both IORT
and PORT. The loco-regional control rate was
significantly better in the adjuvant therapy group
compared with the resection alone group, 80% vs
31%, respectively. The actuarial 5-year survival also
was significantly better in the resection+IORT+
PORT group (39.2%) compared with the resection
alone group (13.5%).
A recent study from the Academic Medical Center in
Amsterdam [6] examined 91 patients with resected
hilar cholangiocarcinoma. Twenty patients had no
adjuvant radiation therapy, 30 patients had external
beam radiotherapy (46.0+11.3 Gy) and 41 patients
had combination external beam therapy (42.3+4.9 Gy)
and intraluminal brachytherapy with iridium
seeds (10.4+1.7 Gy). Overall median survival was
significantly longer in patients treated with adjuvant
radiotherapy than in those who underwent resection
without additional radiotherapy (24 months vs
8 months). The combination of external radiation and
brachytherapy did not result in longer survival than
external irradiation alone (21 months and 30 months,
respectively).
In many of these retrospective reports, patients
receiving radiotherapy tended to have more favourable,
often resectable tumours, and were relatively fit. These
patients who have undergone radiotherapy, and are
expected to have good outcomes, have been compared
with patients with unresectable tumours, metastatic
disease, or poor performance status who did not receive
radiotherapy. Thus, the fact that patients receiving
radiotherapy in these analyses have survived longer is
not surprising.
To more objectively assess the benefit, if any, of
adjuvant radiotherapy, we have previously reported the
results of a prospective trial of adjuvant radiation
therapy for patients with operable perihilar cholangio-
carcinoma at the Johns Hopkins Hospital [7].
All patients were surgically staged and found to have
cholangiocarcinoma localized to the perihilar biliary
tree, with no evidence of intraperitoneal or distant
metastases. All patients had histological confirmation
of malignancy. Patients were included with either
resected, partialIy resected, or unresected tumour, but
were stratified on the basis of extent of resection.
A Karnofsky performance status of at least 60 at the
time of hospital discharge was required for inclusion.
In addition, patients had to be fit to begin radiation
therapy within 8 weeks after surgery.
During the 5-year study period, 50 patients were
evaluated, whereas 34 were excluded. Radiation
ranged from 45 to 63 Gy and consisted of external
beam plus iridium-I92 seeds for resected patients and
external beam plus cone down port for palliated
patients. None of the patients received adjuvant
chemotherapy. Patients undergoing curative resection
survived significantly longer than patients undergoing
operative palliation. Among 31 resected patients,
radiation had no effect on mean (24 vs 24 months),
median, or actuarial survival. Similarly, among
19 palliated patients radiation had no effect on mean
(10 vs 13 months), median, or actuarial survival. Thus,
for all 50 patients, adjuvant radiation therapy had
no effect on overall survival (Figure 1). Moreover,
multivariate analysis identified resection as the only
positive predictive factor for prolonged survival.
Chemotherapy
Most trials evaluating the efficacy of chemotherapeutic
agents in cholangiocarcinoma represent small
single institution phase II trials. These trials often
combine both gallbladder cancers and intrahepatic
and distal cholangiocarcinomas with perihilar
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cholangiocarcinomas. Several small studies of single
agent systemic chemotherapy regimens for
unresectable cholangiocarcinoma using drugs such
as 5-fluorouracil (5-FU), methansulfon-m-anisidide,
cisplatin, rifampicin, mitomycin C, paclitaxel and
gemcitabine have been reported. In general, these
trials have shown little efficacy, with partial response
rates ranging from 0% to 9% and median survivals
between 2 and 12 months [8].
The most extensively investigated chemotherapeutic
agent for cholangiocarcinoma has been 5-FU.
A prospective randomized trial by the Eastern
Cooperative Oncology Group (ECOG) [9] comparing
oral 5-FU to oral 5-FU+streptozotocin (Stz) and oral
5-FU+methyl-CCNU (MeCCNU) in 34 patients
with unresectable cholangiocarcinoma demonstrated
a partial response rate of only 9%. The addition of
either streptozotocin or MeCCNU to oral 5-FU
therapy did not improve the response rate and was
associated with a decrease in median survival from 26
weeks for 5-FU alone to 12 weeks for 5-FU+Stz and
8 weeks for 5-FU+MeCCNU.
Because of the poor response rates with single agent
therapy for cholangiocarcinoma, several authors have
used combination chemotherapy in an attempt to
achieve better response rates and longer survival
(Table I). Cholangiocarcinomas are believed to have
a large percentage of hypoxic cells since they appear
as hypovascular lesions on abdominal imaging and
angiography. Therefore, mitomycin C has been
proposed as a potential chemotherapeutic agent for
cholangiocarcinoma because high levels of the drug can
be achieved in bile and because it has a preferential
toxicity in hypoxic cells.
In one study a regimen of intravenous bolus cisplatin
(60 mg/m2) and epirubicin (50 mg/m2) was given on
day 1, and repeated every 3 weeks followed by 5-FU
200 mg/m2/day given as a continuous 24-hour infusion
throughout the treatment course in nine patients with
advanced extrahepatic cholangiocarcinoma (Table I).
Two patients (22%) had a partial response with
duration of response of 10 months, three patients
(33%) had stable disease and four patients (44%) had
evidence of disease progression on therapy. The
median survival was 5 months (range 3–13 months).
In another study the efficacy of combination therapy
with 5-FU, doxorubicin, and mitomycin C (FAM
regimen) was investigated in 14 patients with
unresectable cholangiocarcinoma (Table I). A partial
response (50% or greater reduction in tumour size by
imaging) was obtained in four patients (29%). The
median duration of response was 8.5 months, and the
median survival was 11.5 months. An additional six
(43%) patients had evidence of disease stabilization for
a median of 6.7 months.
Patt and colleagues [10] used systemic intravenous
5-FU and subcutaneous recombinant human interferon-
alpha-2b (rIFN-alpha-2b) in 25 patients with
cholangiocarcinoma. Patients received a continuous
infusion of 750 mg/m2/d of 5-FU on days 1–5 and a
subcutaneous injection of 5 MU/m2 of rIFN-alpha-2b
on days 1, 3 and 5. Treatment cycles were repeated every
14 days for 8 weeks. Nine of 24 (38%) assessable patients
had a partial response. The median time to disease
progression was 9.5 months, and the median survival
time was 12 months. Unfortunately, none of the above
regimens has been proven to enhance survival in patients
with cholangiocarcinoma.
Chemoradiation
Combinations of chemotherapy with radiation have
been attempted for many localized tumours. The
benefit of combining chemotherapeutic agents with
radiosensitizing properties such as 5-FU, mitomycin C
and cisplatin with radiation has been demonstrated
with several gastrointestinal tumour types but not for
biliary tract cancers. Nevertheless, chemoradiation has
been applied to patients with cholangiocarcinoma at
several centres. In general, these regimens are well
tolerated; however, the number of patients has been
small, both resected and unresected patients have been
treated, and no control patients have been included.
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Figure 1. Actuarial survival for 50 patients with perihilar cholangio-
carcinoma with (n=23) and without (n=27) adjuvant radiation
therapy. From Pitt et al. [7].
Table I. Systemic chemotherapy for unresectable perihilar
cholangiocarcinoma*
Chemotherapy n
Response
rate
Median
survival
5-FU 12 9% 6 months
5-FU, cisplatin,
epirubicin 9 22% 5 months
5-FU, adriamycin,
mitomycin C 14 29% 11.5 months
5-FU, methotrexate,
leukovorin, cisplatin 10 30% 4 months
5-FU, interferon-alpha 25 38% 12 months
5-FU, leukovorin,
mitomycin C 7 57% 17 months
5-FU, 5-fluorouracil.
*Adapted from Todoroki [8].
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In a recent retrospective review Kim et al. [11]
used adjuvant external beam radiotherapy (40 Gy)
combined with concomitant bolus 5-FU (500 mg/m2)
chemotherapy for the first 3 days of each 2 weeks of
radiation in 84 patients with extrahepatic cholangio-
carcinoma. Monthly maintenance chemotherapy with
5-FU (500 mg/m2, first 5 days of the month) was then
administered for 1 year. The overall 5-year actuarial
survival rate was 31%. When patients were stratified by
residual tumour the 5-year survival rate was 36% for
patients with negative microscopic margins at the time
of resection, 35% for patients with positive microscopic
margins and 0% for patients with gross residual disease.
However, the 5-year actuarial survival was only 14%
overall for the subgroup with perihilar tumours.
We have recently reported 140 patients with biliary
malignancies managed at the Medical College of
Wisconsin over a 12-year period. One hundred and
eleven (79%) had cholangiocarcinomas, and 72 of
these (65%) were perihilar. Over the past 4 years of this
analysis, improved staging, active biliary stenting and
aggressive surgery led to improved survival (p50.01,
70% at 44 months) in resected patients (Figure 2A).
Chemoradiation with confocal radiation, 5-FU and
gemcitabine was employed more frequently in the
patients resected since 1998. In addition, this regimen
of chemoradiation resulted in better survival (p50.05)
than a regimen with less sophisticated radiation and
5-FU alone which was used in the early 1990s
(Figure 2B).
In 2001–2002 a questionnaire was sent to members
of the International Hepato-Pancreato-Biliary Asso-
ciation, the American Hepato-Pancreato-Biliary
Association and the American College of Surgeons
Oncology Group to assess current trends in adjuvant
therapy for biliary malignancies [12]. Responses
were received from 331 authorities at 262 centres
in 39 countries worldwide. Presently, adjuvant
chemoradiation is used at the majority of centres, with
this approach being employed most frequently in the
Americas (71%) followed by the Asia/Pacific region
(55%) and Europe (29%) (Table II). Interestingly,
considerable enthusiasm (88%) for a prospective
randomized trial was expressed by the respondents.
However, to date, a multi-institutional, multinational
trial has not been performed.
Summary
Despite significant advances in the surgical manage-
ment of perihilar cholangiocarcinoma, the only
chance for long-term survival remains complete
resection with negative margins. Unfortunately, this
goal is achievable in only a minority of patients.
To date, radiation therapy and chemotherapy alone
have been disappointing in prolonging survival
in these patients. Therefore, to improve outcomes in
perihilar cholangiocarcinoma, new agents or strategies
to deliver adjuvant therapy are needed. Possible
strategies include increasing the dose or fields of
radiation; identifying active chemotherapeutic agents;
or switching to a preoperative, neoadjuvant approach.
In addition, more research needs to be done on the
effect, if any, of hormones such as cholecystokinin
or somatostatin on the growth of human cholangio-
carcinomas. Ideally, prospective randomized trials
should be performed to determine whether new
strategies or agents are beneficial.
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Figure 2. (A) Actuarial survival for resected patients by time period.
From Nakeeb et al. [2]. (B) Actuarial survival for patients treated
with chemoradiation by time period. From Nakeeb et al. [2].
Table II. Current use of adjuvant radiation therapy, chemotherapy,
and chemoradiation in biliary malignancies*
Treatment Americas Asia/Pacific Europe Total
Radiation therapy 70%# 40% 29% 59%
Chemotherapy 66% 79% 68% 68%
Chemoradiation 71%# 55% 29% 63%
*Adapted from Pitt et al. [12].
# p50.05 versus other regions.
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